Hertzel Gerstein, ADA 2022: The ELIXA biomarker study, protein biomarkers to identify cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome
The ELIXA biomarker study evaluated protein biomarkers as clinical risk factors to identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death. Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada) discusses the outcomes of the ELIXA biomarker study and the implications of the findings for clinical practice.
The abstract entitled ‘Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Please can you describe the rationale for investigating novel protein biomarkers as risk factors for cardiovascular outcomes? (0:27)
- How did the ELIXA biomarker study evaluate potential novel protein risk factors and what were its key findings? (1:42)
- In your opinion, what are the implications of these results for clinical practice? (3:12)
Disclosures: Hertzel Gerstein is on the advisory board and a consultant for Sanofi. Hertzel Gerstein has received grant/research support and honorarium from Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022 in diabetes
2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!